Plasma concentration of cross-linked fibrin degradation product (D-dimer) and the risk of future myocardial infarction among apparently healthy men

Circulation

Volumn 90, Issue 5, 1994, Pages 2236-2240

  Ridker, Paul M ^a   Hennekens, Charles H ^a,b   Cerskus, Andrew ^c   Stampfer, Meir J ^a,d  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c Harvard School of Public Health ^*  (Canada)

^d HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

D dimer; epidemiology; fibrin degradation products; infarction; risk factors

Indexed keywords

ACETYLSALICYLIC ACID; BETA CAROTENE; FIBRIN DEGRADATION PRODUCT;

ADULT; AGE; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY THROMBOSIS; DIAGNOSTIC VALUE; DOUBLE BLIND PROCEDURE; FIBRINOLYSIS; HEART INFARCTION; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; RISK FACTOR; SMOKING;

EID: 0028126597     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.90.5.2236     Document Type: Article

References (30)

1. Wilhelmsen L, Svärdsudd K, Korsan-Bengtsen K, Larsson B, Welin L, Tibblin G. Fibrinogen as a risk factor for stroke and MI. N Engl J Med. 1984;311:501-505.
2. Meade TW, Mellows S, Brozovic M, Miller GJ, Chakrabarti RR, North WR, et al. Haemostatic function and ischemic heart disease: principal results of the Northwick Park Heart Study. Lancet. 1986; 2:533-537.
3. Kannel WB, Wolf PA, Castelli WP, D'Agostino RB. Fibrinogen and risk of cardiovascular disease: the Framingham Study. JAMA. 1987;258:1183-1186.
4. Meade TW, Cooper J, Miller GJ, Howarth DJ, Stirling Y. Antithrombin III and arterial disease. Lancet. 1991;337:850-851.
5. Trip MD, Manger Cats V, van Capelle FJI, Vreeken J. Platelet hyperreactivity and prognosis in survivors of MI. N Engl J Med, 1990;322:1549-1554.
6. Elwood PC, Renaud S, Sharp DS, Beswick AD, O'Brien JR, Yarnell JWG. Ischemic heart disease and platelet aggregation: the Caerphilly Collaborative Heart Disease Study. Circulation. 1991; 83:38-44.
7. Thaulow E, Erikssen J, Sandvik L, Stormorken H, Cohn PF. Blood platelet count and function are related to total and cardiovascular death in apparently healthy men. Circulation. 1991;84:613-617.
8. Hamsten A, Wimon B, DeFaire U, Blomback M. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of MI. N Engl J Med. 1985;313:1557-1563.
9. Hamsten A, Walldius G, Szamosi A, Blombäck M, deFaire U, Dahlén G, Wiman B. Plasminogen activator inhibitor in plasma: risk factor for recurrent MI. Lancet. 1987;2:3-9.
10. Ridker PM, Vaughan DE, Stampfer MJ, Manson JE, Hennekens CH. Endogenous tissue-type plasminogen activator and risk of MI. Lancet. 1993;341:1165-1168.
11. Ridker PM, Hennekens CH, Stampfer MJ, Manson JE, Vaughan DE. Prospective study of endogenous tissue plasminogen activator and risk of stroke. Lancet. 1994;343:940-943.
12. Hunt FA, Rylatt DB, Hart R-A, Bendesen PG. Serum cross-linked fibrin (SDP) and fibrinogen/fibrin degradation products (FDP) in disorders associated with activation of the coagulation or fibrínolytic systems. Br J Haematol. 1985;60:715-722.
13. Francis SW, Marder VJ. A molecular model of plasmic degradation of cross-linked fibrin. Semin Thromb Hemost. 1982;8:25-35.
14. Bick RL. The clinical significance of fibrinogen degradation products. Semin Thromb Hemost. 1982;8:302-330.
15. Goldhaber SZ, Vaughen DE, Tumeh SS, Loscalzo J. Utility of cross-linked fibrin degradation products in the diagnosis of pulmonary embolism. Am Heart J. 1988;116:505-508.
16. Bounameaux H, Cirafici P, deMoerloose P, Schneider P-A, Slosman D, Reber G, Unger PF. Measurement of D-dimer in plasma as diagnostic aid in suspected pulmonary embolism. Lancet. 1991;337: 196-200.
17. Bounameaux H, Schneider PA, Reber G, deMoerloose P, Krahenbuhl B. Measurement of plasma D-dimer for diagnosis of deep venous thrombosis. Am J Clin Pathol. 1989;91:82-85.
18. Steering Committee of the Physicians' Health Study Research Group. Final report of the aspirin component of the ongoing Physicians' Health Study. N Engl J Med. 1989;321:129-135.
19. World Health Organization. Ischemic heart disease registers: report of the Fifth Work Group, including a second revision of the operating protocol. Copenhagen, Denmark: WHO Regional Office for Europe; April 26-29, 1971.
20. Declerck PJ, Mombaerts P, Holvoet P, De Mol M, Collen D. Fibrinolytic response and fibrin fragment D-dimer levels in patients with deep vein thrombosis. Thromb Haemost. 1987;58:1025-1029.
21. Stampfer MJ, Sacks FM, Salvani S, Willett WC, Hennekens CH. A prospective study of cholesterol, apolipoproteins, and the risk of Ml. N Engl J Med. 1991;325:373-381.
22. Ridker PM, Vaughan DE, Stampfer MJ, Manson JE, Shen C, Newcomer LM, Goldhaber SZ, Hennekens CH. Baseline fibrinolytic state and the risk of future venous thrombosis: a prospective study of endogenous tissue-type plasminogen activator and plasminogen activator inhibitor. Circulation. 1992;85:1822-1827.
23. Ridker PM, Hennekens CH, Stampfer MJ. A prospective study of lipoprotein(a) and the risk of MI. JAMA. 1993;270:195-199.
24. Fowkes FGR, Lowe GDO, Housley E, Rattray A, Rumley A, Elton RA, MacGregor IR, Dawes J. Cross-linked fibrin degradation products, progression of peripheral arterial disease, and risk of coronary heart disease. Lancet. 1993;342:84-86.
25. Ridker PM, Hennekens CH. Hemostatic risk factors for coronary heart disease. Circulation. 1991;83:1098-1100.
26. Smith EB, Thompson WD, Crosbie L, Stirk CM. Fibrinogen/fibrin in atherogenesis. Eur J Epidemiol. 1992;8(suppl 1):83-87.
27. Smith EB, Keen GA, Grant A, Stirk C. Fate of fibrinogen in human arterial intima. Arteriosclerosis. 1990;10:263-275.
28. Francis CW, Connaghan DG, Scott WL, Marder VJ. Increased plasma concentration of cross-linked fibrin polymers in acute MI. Circulation. 1987;75:1170-1177.
29. van Beek EJR, van den Ende B, Berckmans RJ, van der Heide YT, Brandjes DPM, Sturk A, ten Cate JW. A comparative analysis of D-dimer assays in patients with clinically suspected pulmonary embolism. Thromb Haemost. 1993;70:408-413.
30. Ridker PM. An epidemiologic assessment of thrombotic risk factors for cardiovascular disease. Curr Opin Lipid. 1992;3:285-290.